Latest Breaking News On - Huntington disease centre - Page 1 : comparemela.com

uniQure Inc.: uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

uniQure Inc.: uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited kingdomChiara russoTom maloneMariae cantorWalid abi saabStefan klotterQueen square institute of neurologyCure huntington disease initiativeSecurities exchangeNational hospital for neurology neurosurgeryHuntington disease centreUniversity college londonUs securities exchange commissionPhasei ii clinical programEuropean phase

uniQure (QURE) Issues Update on Phase I/II Clinical Trials of AMT-130

uniQure (QURE) Issues Update on Phase I/II Clinical Trials of AMT-130
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomWalid abi saabNational hospital for neurology neurosurgeryCure huntington disease initiativeQueen square institute of neurologyUniversity college londonHuntington disease centreEuropean phaseEdward wildQueen square instituteNational hospitalCure huntingtonDisease initiativeTotal functional capacityDiagnostic classification levelTotal motor score

UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease -December 19, 2023 at 07:05 am EST

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural.

United kingdomNoord hollandMariae cantorWalid abi saabChiara russoTom maloneSqure incQueen square institute of neurologyCure huntington disease initiativeSecurities exchangeNational hospital for neurology neurosurgeryUs securities exchange commissionUniversity college londonGlobenewswire incHuntington disease centrePhasei ii clinical program

UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease -December 19, 2023 at 07:06 am EST

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural.

Noord hollandUnited kingdomChiara russoTom maloneWalid abi saabMariae cantorPhasei ii clinical programNational hospital for neurology neurosurgeryUs securities exchange commissionHuntington disease centreUniversity college londonCure huntington disease initiativeSecurities exchangeQueen square institute of neurologyEuropean phaseEdward wild

Rgenta Therapeutics Announces Formation of Repeat Expansion Diseases Focused Scientific Advisory Board

/PRNewswire/ Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB). REDs SAB.

United kingdomUnited statesSarah tabriziRichardh myersZhiping wengNicholas johnsonDarren moncktonAvedisian school of medicine at boston universityDepartment of neurology at virginia commonwealth universityUnited kingdom academy of medical sciencesParty parliamentary group for huntingtonHuntington disease centreEuropean dystrophia myotonica associationEngland huntington disease center without wallsMyotonic dystrophy foundation united statesMyotonic dystrophy support group united kingdom